Biovica International
16.11.2021 09:38:17 CET | ACCESS Newswire | Press release
UPPSALA, SWEDEN / ACCESSWIRE / November 16, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)
Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on data presented at the ISPOR 2021 meeting. The model's results show that monitoring with DiviTum®TKa may achieve savings of up to three times the extra spend relative to current management of metastatic breast cancer patients.
Care for metastatic breast cancer patients is a large burden on healthcare systems due to cost of therapies, cost of monitoring tests, and management of side effects. The results from this study show that adding DiviTumTKa to care could give a net reduction in costs of up to three times the spend on the new test. The savings come from a decrease in the usage of other monitoring tools such as CT scans and bone scans, and from shortening the amount of time a patient receives expensive medical treatments that ultimately prove to be ineffective.
"Our analysis showed that inclusion of DiviTum®TKa could reduce use of a substantial proportion of traditional monitoring. If use of DiviTum®TKa can also predict lack of benefit from costly CDK4/6i therapy and clinicians then act on that information in a timely fashion, our model suggests that this will result in substantial cost savings to patients and health plans," said Scott D. Ramsey from the Fred Hutchison Cancer Research Center.
"This analysis reinforces our belief that DiviTum®TKa will improve the lives of patients and reduce costs in healthcare. From discussions with patients, we also know that they prefer a regular blood test as a better option than current monitoring practices." said Anders Rylander, CEO of Biovica.
The study publication is included in the November 2021 issue of the Journal of Medical Economics https://doi.org/10.1080/13696998.2021.2003674
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
Attachments
Biovica's DiviTum®TKa results published in Journal of Medical Economics
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/673068/Biovicas-DiviTumRTKa-Results-Published-in-Journal-of-Medical-Economics
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals and Fiore-backed Springbok Ventures Announce Upsize of Non-Brokered Private Placement10.8.2026 20:30:00 CEST | Press release
Not for distribution to United States newswire services or for dissemination in the United States. THUNDER BAY, ON / ACCESS Newswire / August 10, 2026 / Clean Air Metals Inc. ("Clean Air Metals") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) and Springbok Ventures Inc. ("Springbok") are pleased to announce that, further to the joint news release dated August 1, 2026, due to strong market demand they have agreed to increase the size of the previously announced non-brokered private placement of subscription receipts (the "Offering") to $6.1 million, as follows: 10,000,000 subscription receipts of Springbok (the "Springbok Subscription Receipts") at a price of $0.50 per Springbok Subscription Receipt; and 2,000,000 subscription receipts of Clean Air Metals (the CAM Subscription Receipts") at a price of $0.55 per CAM Subscription Receipt. Each Springbok Subscription Receipt will, subject to satisfaction or waiver of certain escrow release conditions, automatically convert in accordance with its terms
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer10.8.2026 10:00:00 CEST | Press release
ROCKVILLE, MD / ACCESS Newswire / August 10, 2026 / ABL Inc and Ascend Advanced Therapies today announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further strengthening the Company's commercial leadership and its commitment to supporting customers with the development and manufacturing of viral vectors, vaccines, biologics and advanced therapies. Suman brings nearly two decades of experience and leadership, supporting emerging biotech and large pharma within the biopharmaceutical industry. He will be responsible for leading the company's global commercial organization, including business development, marketing and strategic partnership functions. As the industry continues to evolve, customers are now increasingly seeking end-to-end CDMO partners capable of translating science and delivering impeccable service whilst reducing technical, operational and manufacturing risks. Through his experience with programs ranging from early-stage development to commercia
Innodata Reports Record Second Quarter 2026 Results6.8.2026 22:05:00 CEST | Press release
Revenue Up 58% Year-Over-Year, Beats Consensus by 7% Adjusted EBITDA of $25.4 Million, Beats Consensus by 50% Adjusted Gross Margin Expands to 49% Announces Planned Leadership Transition Effective September 30: Rahul Singhal to Become President and CEO, Jack Abuhoff to Become Executive Chairman NEW YORK, NY / ACCESS Newswire / August 6, 2026 / INNODATA INC. (NASDAQ:INOD) today reported results for the second quarter ended June 30, 2026. Revenue of $92.1 million, representing 58% year-over-year revenue growth. Adjusted Gross Profit of $45.4 million, representing Adjusted Gross Margin of 49%.* Adjusted EBITDA of $25.4 million, or 27.5% of revenue, an increase of $12.1 million from $13.2 million in the same period last year.* Net income of $14.4 million, or $0.43 per basic share and $0.41 per diluted share for the three-month period ended June 30, 2026, compared to net income of $7.2 million, or $0.23 per basic share and $0.20 per diluted share, in the same period last year. Cash, cash eq
Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook6.8.2026 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / August 6, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our") reported record results for the second quarter of 2026. "Through the first half of the year, the business continues to outperform our expectations, driven by exceptional demand across our end-markets and strong conversion of our new business pipeline. Of the approximately $750 million in our pipeline, we secured initial orders that provide visibility to approximately $200 million of revenue over the next five years," said Dirkson Charles, Loar Holdings Chief Executive Officer and Executive Co-Chairman of the Board of Directors. Second Quarter 2026 Net sales of $171.6 million, up 39.4% compared to the prior year's quarter. Net income of $16.7 million, equal to the prior year's quarter. Diluted earnings per share of $0.18 compared to $0.17 for the prior year's quarter. Adjusted EBITDA of $69.4 million up 47.4% compared to the prior year's quarter. Net income
RE Royalties Announces Third Investment in Solaris Energy's Portfolio and Letter of Intent for Expanded Royalty Partnership for a Further US$62.7 Million5.8.2026 12:00:00 CEST | Press release
All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further investment of US$1 million toward the purchase of royalties on a portfolio of Solaris Energy Inc.'s ("Solaris") distributed generation ("DG") solar projects located throughout the United States. The Company also announced that it has entered into a non-binding Letter of Intent ("LOI") of up to US$67.5 million with Solaris to pursue an expanded royalty funding partnership across Solaris' current and future project pipeline. This third tranche payment brings RE Royalties' total investment in royalties over Solaris' portfolio to US$4.8 million. The Company previously funded US$3 million, as announced on January 7, 2026, followed by US$800,000 as announced on February 9, 2026. Solaris' Portfolio consists of 16 distributed generation solar projects totaling approximately 15.2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom